StageSeries B - III | Alive
Last Raised$25M | 5 mos ago
About Immune-Onc Therapeutics
Immune-Onc provides biological services. The company helps cancer patients through cancer immunotherapy and biological development treatments including tumor microenvironment and immune suppressive pathways to develop biotherapeutics. Immune-Onc was founded in 2016 and is based in Palo Alto, California.
Missing: Immune-Onc Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Immune-Onc Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Immune-Onc Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Immune-Onc Therapeutics is included in 3 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Immune-Onc Therapeutics Patents
Immune-Onc Therapeutics has filed 6 patents.
The 3 most popular patent topics include:
- Autoimmune diseases
- Experimental cancer drugs
- Cancer treatments
Piperazines, Hepatotoxins, Autoimmune diseases, Lactams, Phenols
Piperazines, Hepatotoxins, Autoimmune diseases, Lactams, Phenols
Latest Immune-Onc Therapeutics News
May 8, 2023
Dublin, IRELAND Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Checkpoint inhibitors - Competitive landscape, 2023" report provides comprehensive insights about 180+ companies and 250+ drugs in Checkpoint inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights In April 2023, Enlivex Therapeutics Ltd. announced a clinical collaboration agreement with BeiGene. The Company entered into this collaboration to evaluate the safety and efficacy of AllocetraT, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors, a part of the Company's ongoing Phase I/II clinical trial. In January 2023, CARsgen Therapeutics Holdings Limited had announced CARsgen's execution of a collaboration agreement with F. Hoffmann-La Roche Ltd to evaluate CARsgen's investigational drug AB011, the first humanized monoclonal antibody against Claudin18.2 (CLDN18.2) that received IND clearance globally, in combination with atezolizumab, Roche's PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with gastric or gastroesophageal junction carcinoma . Under the terms of the agreement, Roche will be responsible for operation and conduct of the trial while both companies co-share the costs of the AB011 treatment arms in the study. In January 2023, Teon Therapeutics, announced that it has entered into the clinical trial collaboration agreement with Merck. The agreement is for the combination arm of Teon's ongoing, two-armed, open-label, dose escalation and expansion clinical study and will evaluate Teon's oral, immune response modifier, TT-816, in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for patients with advanced solid tumors. In October 2022, Immune-Onc Therapeutics, Inc. ("Immune-Onc"), announced it has entered into a clinical trial collaboration and supply agreement with BeiGene to evaluate Immune-Onc's first-in-class myeloid checkpoint inhibitors, IO-108 and IO-202, in combination with BeiGene's anti-PD-1 antibody, tislelizumab, as part of its clinical development programs in China. In October 2022, Exelixis, Inc. announced the expansion of its June 2021 Clinical Trial Collaboration and Supply Agreement with Bristol-Myers Squibb Company to include the use of the fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial (NCT05176483), which is evaluating XL092 in combination with multiple immune checkpoint inhibitors (ICIs) in advanced solid tumors. Current Treatment Scenario and Emerging Therapies: How many companies are developing Checkpoint inhibitors drugs? How many Checkpoint inhibitors drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Checkpoint inhibitors? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Checkpoint inhibitors therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Checkpoint inhibitors and their status? What are the key designations that have been granted to the emerging and approved drugs? Key Players
Immune-Onc Therapeutics Frequently Asked Questions (FAQ)
When was Immune-Onc Therapeutics founded?
Immune-Onc Therapeutics was founded in 2016.
Where is Immune-Onc Therapeutics's headquarters?
Immune-Onc Therapeutics's headquarters is located at 795 San Antonio Rd, Palo Alto.
What is Immune-Onc Therapeutics's latest funding round?
Immune-Onc Therapeutics's latest funding round is Series B - III.
How much did Immune-Onc Therapeutics raise?
Immune-Onc Therapeutics raised a total of $106.32M.
Who are the investors of Immune-Onc Therapeutics?
Investors of Immune-Onc Therapeutics include Leukemia & Lymphoma Society, Proxima Ventures, WuXi Biologics, Triwise Capital Management, Vivo Capital and 12 more.
Who are Immune-Onc Therapeutics's competitors?
Competitors of Immune-Onc Therapeutics include Pionyr Immunotherapeutics, Neon Therapeutics, Forty Seven, NextCure, Harpoon Therapeutics and 9 more.
Compare Immune-Onc Therapeutics to Competitors
OncoResponse develops therapeutic antibodies for the treatment of cancer by probing the adaptive immune system of cancer patients who have responded exceptionally well to Checkpoint Inhibition (CPI). It develops cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. The company was founded in 2015 and is based in Seattle, Washington.
ImmunoMet Therapeutics is a development-stage biotechnology company focused on utilizing cellular metabolism to develop anti-tumor and immuno-oncology therapies. The company develops a molecule that targets the oxidative phosphorylation (OXPHOS) pathway in mitochondria and decreases aberrant cell growth in fibrosis and selects cancer cells. It was founded in 2015 and is based in Houston, Texas.
Fortis Therapeutics is an immuno-oncology biotech company focused on developing new antibody-drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.
Pionyr Immunotherapeutics is a clinical-stage biotechnology company. It develops cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. Pionyr Immunotherapeutics was formerly known as Precision Immune. The company was founded in 2015 and is based in South San Francisco, California.
Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The Company's technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body's natural immune system to fight cancer.
Epsilogen is engaged in developing immunoglobulin E (IgE) antibodies to treat cancer. Its IgE has several key features that make it ideal for treating solid tumors including greater potency, enhanced tumor access, and a long tissue half-life. It was founded in 2016 and is based in London, United Kingdom.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.